Titre : Comptes-rendus de sortie des patients

Comptes-rendus de sortie des patients : Questions médicales fréquentes

Termes MeSH sélectionnés :

Quantitative Structure-Activity Relationship
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Comptes-rendus de sortie des patients : Questions médicales les plus fréquentes", "headline": "Comptes-rendus de sortie des patients : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Comptes-rendus de sortie des patients : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-11", "dateModified": "2025-04-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Comptes-rendus de sortie des patients" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Dossiers médicaux", "url": "https://questionsmedicales.fr/mesh/D008499", "about": { "@type": "MedicalCondition", "name": "Dossiers médicaux", "code": { "@type": "MedicalCode", "code": "D008499", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "N06.850.520.308.940.968" } } }, "about": { "@type": "MedicalCondition", "name": "Comptes-rendus de sortie des patients", "alternateName": "Patient Discharge Summaries", "code": { "@type": "MedicalCode", "code": "D063886", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Christine Maria Schwarz", "url": "https://questionsmedicales.fr/author/Christine%20Maria%20Schwarz", "affiliation": { "@type": "Organization", "name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria." } }, { "@type": "Person", "name": "Magdalena Hoffmann", "url": "https://questionsmedicales.fr/author/Magdalena%20Hoffmann", "affiliation": { "@type": "Organization", "name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria. magdalena.hoffmann@medunigraz.at." } }, { "@type": "Person", "name": "Gerald Sendlhofer", "url": "https://questionsmedicales.fr/author/Gerald%20Sendlhofer", "affiliation": { "@type": "Organization", "name": "Research Unit for Safety and Sustainability in Healthcare, c/o, Division of Plastic, Aesthetic and Reconstructive Surgery, Department of Surgery , Medical University of Graz, Graz, Austria." } }, { "@type": "Person", "name": "Thomas R Campion", "url": "https://questionsmedicales.fr/author/Thomas%20R%20Campion", "affiliation": { "@type": "Organization", "name": "Department of Population Health, Weill Cornell Medicine, New York, NY 10065, United States." } }, { "@type": "Person", "name": "Rebecca Brundin-Mather", "url": "https://questionsmedicales.fr/author/Rebecca%20Brundin-Mather", "affiliation": { "@type": "Organization", "name": "Department of Critical Care Medicine, University of Calgary, Calgary T2N 4Z6, Alberta, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Design, Synthesis, Antibacterial Evaluation, Three-Dimensional Quantitative Structure-Activity Relationship, and Mechanism of Novel Quinazolinone Derivatives.", "datePublished": "2023-02-21", "url": "https://questionsmedicales.fr/article/36807581", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.jafc.2c07264" } }, { "@type": "ScholarlyArticle", "name": "Automated machine learning approach for developing a quantitative structure-activity relationship model for cardiac steroid inhibition of Na", "datePublished": "2023-06-24", "url": "https://questionsmedicales.fr/article/37354314", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s43440-023-00508-x" } }, { "@type": "ScholarlyArticle", "name": "Multivariate image analysis applied to quantitative structure-activity relationships and docking studies of recent hydroxyphenylpyruvate deoxygenase inhibitors.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37021557", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/jsfa.12608" } }, { "@type": "ScholarlyArticle", "name": "Artificial Intelligence-Based Quantitative Structure-Property Relationship Model for Predicting Human Intestinal Absorption of Compounds with Serotonergic Activity.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37070956", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1021/acs.molpharmaceut.2c01117" } }, { "@type": "ScholarlyArticle", "name": "Development of a quantitative structure-activity relationship model for predicting quantum yield of hydroxyl radical generation from organic compounds.", "datePublished": "2023-01-25", "url": "https://questionsmedicales.fr/article/36504232", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1039/d2em00396a" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Environnement et santé publique", "item": "https://questionsmedicales.fr/mesh/D004778" }, { "@type": "ListItem", "position": 3, "name": "Santé publique", "item": "https://questionsmedicales.fr/mesh/D011634" }, { "@type": "ListItem", "position": 4, "name": "Méthodes épidémiologiques", "item": "https://questionsmedicales.fr/mesh/D004812" }, { "@type": "ListItem", "position": 5, "name": "Collecte de données", "item": "https://questionsmedicales.fr/mesh/D003625" }, { "@type": "ListItem", "position": 6, "name": "Documents", "item": "https://questionsmedicales.fr/mesh/D011996" }, { "@type": "ListItem", "position": 7, "name": "Dossiers médicaux", "item": "https://questionsmedicales.fr/mesh/D008499" }, { "@type": "ListItem", "position": 8, "name": "Comptes-rendus de sortie des patients", "item": "https://questionsmedicales.fr/mesh/D063886" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Comptes-rendus de sortie des patients - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Comptes-rendus de sortie des patients", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-09", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Comptes-rendus de sortie des patients", "description": "Quels diagnostics sont souvent notés dans un compte-rendu ?\nComment le diagnostic est-il confirmé dans le rapport ?\nQuelle est l'importance du diagnostic dans le compte-rendu ?\nLes diagnostics sont-ils classés dans le compte-rendu ?\nComment les diagnostics influencent-ils le traitement ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Comptes-rendus de sortie des patients", "description": "Quels symptômes sont souvent mentionnés ?\nComment les symptômes sont-ils évalués ?\nLes symptômes changent-ils après le traitement ?\nLes symptômes sont-ils classés par gravité ?\nComment les symptômes influencent-ils le suivi ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Comptes-rendus de sortie des patients", "description": "Quelles mesures préventives sont recommandées ?\nComment la prévention est-elle abordée dans le rapport ?\nLa prévention est-elle personnalisée ?\nQuels conseils de prévention sont souvent inclus ?\nLa prévention est-elle suivie après la sortie ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Comptes-rendus de sortie des patients", "description": "Quels types de traitements sont documentés ?\nComment les traitements sont-ils justifiés ?\nLes traitements sont-ils suivis d'effets secondaires ?\nComment les traitements sont-ils planifiés ?\nLes traitements sont-ils adaptés après la sortie ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Comptes-rendus de sortie des patients", "description": "Quelles complications peuvent survenir après la sortie ?\nComment les complications sont-elles signalées ?\nLes complications sont-elles documentées dans le rapport ?\nComment prévenir les complications après la sortie ?\nLes complications influencent-elles le suivi ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Comptes-rendus de sortie des patients", "description": "Quels facteurs de risque sont souvent identifiés ?\nComment les facteurs de risque sont-ils évalués ?\nLes facteurs de risque influencent-ils le traitement ?\nLes facteurs de risque sont-ils notés dans le compte-rendu ?\nComment réduire les facteurs de risque après la sortie ?", "url": "https://questionsmedicales.fr/mesh/D063886?mesh_terms=Quantitative+Structure-Activity+Relationship&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Quels diagnostics sont souvent notés dans un compte-rendu ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Les diagnostics incluent des maladies aiguës, chroniques et des complications post-opératoires." } }, { "@type": "Question", "name": "Comment le diagnostic est-il confirmé dans le rapport ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic est confirmé par des examens cliniques, des tests de laboratoire et des imageries." } }, { "@type": "Question", "name": "Quelle est l'importance du diagnostic dans le compte-rendu ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Il guide le suivi médical et les traitements à administrer après la sortie." } }, { "@type": "Question", "name": "Les diagnostics sont-ils classés dans le compte-rendu ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent classés par ordre de gravité ou de chronologie." } }, { "@type": "Question", "name": "Comment les diagnostics influencent-ils le traitement ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Ils déterminent les protocoles de traitement et les médicaments prescrits." } }, { "@type": "Question", "name": "Quels symptômes sont souvent mentionnés ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent douleur, fièvre, fatigue et autres signes cliniques pertinents." } }, { "@type": "Question", "name": "Comment les symptômes sont-ils évalués ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont évalués par l'examen physique et les antécédents médicaux du patient." } }, { "@type": "Question", "name": "Les symptômes changent-ils après le traitement ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le compte-rendu note souvent l'évolution des symptômes post-traitement." } }, { "@type": "Question", "name": "Les symptômes sont-ils classés par gravité ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent être classés en fonction de leur impact sur la santé du patient." } }, { "@type": "Question", "name": "Comment les symptômes influencent-ils le suivi ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Ils orientent les recommandations de suivi et les consultations nécessaires." } }, { "@type": "Question", "name": "Quelles mesures préventives sont recommandées ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Les mesures incluent vaccinations, conseils diététiques et exercices physiques." } }, { "@type": "Question", "name": "Comment la prévention est-elle abordée dans le rapport ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Elle est abordée par des recommandations spécifiques basées sur le diagnostic." } }, { "@type": "Question", "name": "La prévention est-elle personnalisée ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elle est souvent adaptée aux antécédents médicaux et au mode de vie du patient." } }, { "@type": "Question", "name": "Quels conseils de prévention sont souvent inclus ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Des conseils sur l'alimentation, l'exercice et l'arrêt du tabac sont fréquents." } }, { "@type": "Question", "name": "La prévention est-elle suivie après la sortie ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le suivi des mesures préventives est souvent recommandé lors des consultations." } }, { "@type": "Question", "name": "Quels types de traitements sont documentés ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements incluent médications, interventions chirurgicales et thérapies physiques." } }, { "@type": "Question", "name": "Comment les traitements sont-ils justifiés ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont justifiés par les diagnostics et l'évolution des symptômes du patient." } }, { "@type": "Question", "name": "Les traitements sont-ils suivis d'effets secondaires ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les effets secondaires potentiels sont souvent notés pour chaque traitement." } }, { "@type": "Question", "name": "Comment les traitements sont-ils planifiés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont planifiés en fonction des besoins individuels et des protocoles médicaux." } }, { "@type": "Question", "name": "Les traitements sont-ils adaptés après la sortie ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des ajustements peuvent être nécessaires en fonction de l'évolution du patient." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après la sortie ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent infections, douleurs persistantes et complications liées aux traitements." } }, { "@type": "Question", "name": "Comment les complications sont-elles signalées ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Elles sont signalées par des observations cliniques et des tests de suivi." } }, { "@type": "Question", "name": "Les complications sont-elles documentées dans le rapport ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles sont souvent documentées pour informer le suivi médical." } }, { "@type": "Question", "name": "Comment prévenir les complications après la sortie ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par des soins appropriés et le respect des recommandations médicales." } }, { "@type": "Question", "name": "Les complications influencent-elles le suivi ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent nécessiter des consultations supplémentaires et des ajustements de traitement." } }, { "@type": "Question", "name": "Quels facteurs de risque sont souvent identifiés ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'âge, les antécédents familiaux et les habitudes de vie." } }, { "@type": "Question", "name": "Comment les facteurs de risque sont-ils évalués ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Ils sont évalués par l'anamnèse et des tests de dépistage spécifiques." } }, { "@type": "Question", "name": "Les facteurs de risque influencent-ils le traitement ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils peuvent orienter les choix thérapeutiques et les recommandations de suivi." } }, { "@type": "Question", "name": "Les facteurs de risque sont-ils notés dans le compte-rendu ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, ils sont souvent notés pour une meilleure gestion des soins futurs." } }, { "@type": "Question", "name": "Comment réduire les facteurs de risque après la sortie ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "La réduction passe par des changements de mode de vie et un suivi médical régulier." } } ] } ] }

Sources (10000 au total)

Design, Synthesis, Antibacterial Evaluation, Three-Dimensional Quantitative Structure-Activity Relationship, and Mechanism of Novel Quinazolinone Derivatives.

Plant bacterial illnesses are common and cause dramatic damage to agricultural goods all over the world, yet there are few efficient bactericides to alleviate them at present. To discover novel antiba...

Automated machine learning approach for developing a quantitative structure-activity relationship model for cardiac steroid inhibition of Na

Quantitative structure-activity relationship (QSAR) modeling is a method of characterizing the relationship between chemical structures and biological activity. Automated machine learning enables comp... The chemical structures and inhibitory activities of 215 CS derivatives were obtained from the scientific literature. Predictive QSAR models were constructed using molecular descriptors, fingerprints,... The best predictive QSAR models were selected based on the LogLoss value. Using these models, the Matthews correlation coefficient, F1 score, and area under the curve of the test dataset were 0.6729, ... The automated machine learning-based QSAR method developed here should be applicable for the time-efficient construction of predictive models using only a small number of compounds....

Multivariate image analysis applied to quantitative structure-activity relationships and docking studies of recent hydroxyphenylpyruvate deoxygenase inhibitors.

Mesotrione is a triketone widely used as an inhibitor of the hydroxyphenylpyruvate deoxygenase (HPPD) enzyme. However, new agrochemicals should be developed continuously to tackle the problem of herbi... The MIA-QSAR models based on van der Waals radii (r... Multivariate image analysis descriptors corroborated by docking studies were capable of modeling the herbicidal activities of 68 triketones reliably. Due to the substituent effects at the triketone fr...

Artificial Intelligence-Based Quantitative Structure-Property Relationship Model for Predicting Human Intestinal Absorption of Compounds with Serotonergic Activity.

Oral medicines represent the largest pharmaceutical market area. To achieve a therapeutic effect, a drug must penetrate the intestinal walls, the main absorption site for orally delivered active pharm...

Development of a quantitative structure-activity relationship model for predicting quantum yield of hydroxyl radical generation from organic compounds.

Organic compounds are capable of generating hydroxyl radicals (˙OH) through their excited triplet states in natural water. It is of significance to reveal the underlying mechanism of the generation an...

In vitro and Quantitative and Structure Activity Relationship (QSAR) evaluation of the antifungal activity of terpenoid constituents of essential oils against Alternaria alternata and Fusarium oxysporum

Fungal genera Alternaria and Fusarium include human and plant pathogenic species. Several antifungals have been used for their control, but excessive use has contributed to resistance development in p... To evaluate in vitro and in silico the antifungal activities of terpenoids against Alternaria alternata and Fusarium oxysporum.... The minimum inhibitory concentration and minimum fungicidal concentration values of 27 constituents of essential oils used against Alternaria alternata and Fusarium oxysporum were evaluated in vitro. ... The evaluated compounds proved to be effective antifungals. Thymol was the most active with a minimum inhibitory concentration of 91.6 ± 28.8 μg/ml for A. alternata and F. oxysporum. Quantitative stru... Terpenoids exhibit relevant antifungal activities that should be incorporated into the study of medicinal chemistry. Inclusion of in silico assays in the in vitro evaluation is a valuable tool in the ...

Three-dimensional quantitative structural-activity relationship and molecular dynamics study of multivariate substituted 4-oxyquinazoline HDAC6 inhibitors.

3D-QSAR models were established by collecting 46 multivariate-substituted 4-oxyquinazoline HDAC6 inhibitors. The relationship of molecular structure and inhibitory activity was studied by comparative ...

Identification of Potent Small-Molecule PCSK9 Inhibitors Based on Quantitative Structure-Activity Relationship, Pharmacophore Modeling, and Molecular Docking Procedure.

The leading cause of atherosclerotic cardiovascular disease (ASCVD) is elevated low-density lipoprotein cholesterol (LDL-C). Proprotein convertase subtilisin/kexin type 9 (PCSK9) attaches to the domai...

An Empirical Quantitative Structure-Activity Relationship Equation Assists the Discovery of High-Affinity Phosphodiesterase 4D Inhibitors as Leads to PET Radioligands.

A positron emission tomography (PET) radioligand for imaging phosphodiesterase 4D (PDE4D) would benefit drug discovery and the investigation of neuropsychiatric disorders. The most promising radioliga...